STAT1 and cancer: Activation of the FGFR signaling inhibits IFNγ-induced STAT1 phosphorylation and the expression of PD-L1, thus protecting cancer cells from the cytotoxic effects of CD8+ T cells [186], thereby supporting resistance to anti-cancer therapies [185].